唑来膦酸联合化疗治疗肺癌骨转移的疗效分析

目的：观察分析唑来膦酸联合化疗治疗肺癌骨转移的临床疗效。方法：选取我院142例肺癌骨转移患者随机分为对照组（74例）和联合组（68例）。对照组患者采用单纯化疗进行治疗；联合组患者采用唑来膦酸联合化疗进行治疗。统计两组患者化疗后生存质量情况、疼痛改善情况、骨病灶控制情况以及不良反应发生率。结果：联合组患者的生存质量改善有效率为86．76％，高于对照组患者的58．11％（P ＜0．05）；联合组患者的疼痛改善有效率为85．29％明显高于对照组患者的55．41％（P ＜0．05）；联合组患者骨病灶控制率为51．47％，明显高于对照组患者的21．62％（P ＜0．05）；联合组患者发热、肌肉酸痛的发生率明显高于对照组患者（P ＜0．05）。结论：采用唑来膦酸联合化疗治疗肺癌骨转移的临床疗效良好，可有效改善病情，控制骨病灶，临床需预防和控制化疗后不良反应。

Efficacy analysis of zoledronic acid combined with chemotherapy treating osseous metastasis of lung cancer

Objective:To observe and analyze the efficacy of zoledronic acid combined with chemotherapy treating osseous me-tastasis of lung cancer.Methods:142 cases of patients with osseous metastasis of lung cancer in our hospital were randomly divided into the control group (74 patients)and the combination group (68 patients).The control group patients were treated with chemotherapy when the combination group patients were treated with zoledronic acid combined with chemotherapy.Quality of life,improvement of the pain,control of bone lesions and the incidence of adverse reactions of all patients were counted.Results:Efficiency rate of quality im-provement of the combination group (86.76%)was significantly higher than that of the control group (58.1 1 %)(P <0.05).The ef-ficiency of rain relief of the combination group (85.29%) was significantly higher than that of the control group (55.41 %) (P <0.05).Control rate of bone lesions of the combination group (5 1 .47%)was significantly higher than that of the control group (21.62%)(P <0.05).The incidence of fever and muscle aches of the combination group were significantly higher than that of the control group (P <0.05).Conclusion:The efficacy of zoledronic acid combined with chemotherapy treating osseous metastasis of lung cancer is significant and can effectively improve the condition,control bone lesions.In clinic,it needs to prevent and control adverse reactions after chemotherapy.